PerkinElmer, focused on the health and safety of people and the environment, has launched a new Lance Ultra cAMP Detection Kit for screening and profiling of G-protein coupled receptors (GPCRs) as tools in the search for potential therapeutics.
PerkinElmer said that the Lance Ultra kit offers three times the sensitivity using at least 80% fewer cells than other kits currently on the market. The new Lance assay has been used for high throughput screening and profiling of GPCRs. The new kit facilitates pharmacological studies of challenging receptors involved in several diseases, including cancer and inflammatory, metabolic and neurodegenerative disorders.
The increased sensitivity of the Lance Ultra cAMP Detection Kit enables scientists to detect low levels of cAMP without the need to re-engineer cell lines, saving time and resources. The assay uses a simple and proven TR-FRET protocol for easy and precise adoption in a range of HTS applications, including 1,536-well formats. The new kit maximizes signal stability and provides new insights into GPCRs, as many high throughput assays fail to generate reproducible data when cAMP levels are very low.
According to the company, Lance Ultra utilizes PerkinElmer’s ULight emission dye, for high efficiency and signal-to-noise ratios. Lance Ultra is optimized for use in high throughput and ultra high throughput screening applications for detection and analysis of protein activity for research purposes.
Martina Bielefeld-Sevigny, vice president and general manager of drug discovery and research reagent solutions, bio-discovery at PerkinElmer, said: “As the drug discovery processes continue to evolve, there is an increased demand for more sensitive methods of measuring responses to GPCRs, which currently form over 40% of all drug targets.
“We’ve addressed this need with the new Lance Ultra cAMP detection kit. Researchers can take advantage of a wider assay window and dynamic range that provides for more accurate results, even when miniaturizing protocols for the most ‘difficult to screen’ targets, including Gi-coupled GPCR antagonist assays.”